Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August.
More than 80 countries where monkeypox is not endemic have reported outbreaks of the viral disease, which the World Health Organisation has declared a global health emergency. Confirmed cases have crossed 27,800 and non-endemic countries Brazil, India and Spain have reported their first deaths from the virus.
Vaccine shortage
On Tuesday, US health officials authorised a plan to stretch out the country’s limited supply of monkeypox vaccine by giving people just one-fifth of the usual dose. The dose-sparing approach calls for intradermal injection of the Jynneos (also known as Imvanex) vaccine just under the skin instead of a full dose into the underlying fat — a practice that may improve immune response. Recipients would still get two shots spaced four weeks apart.
This unusual measure is being taken to supplement the country’s shortfall in vaccine doses. Currently, the US has just 440,000 doses available, which increases to 2 million if the dose-sparing method is used.
Robert Fenton, the White House’s monkeypox response coordinator, told reporters: ‘It’s safe, it’s effective, and it will significantly scale the volume of vaccine doses available for communities across the country.’
European officials are now considering whether to follow suit, given spiraling case numbers on the continent. Speaking to Reuters, a spokesperson for the European Medicines Agency said the agency would ‘discuss the approach’ with Bavarian Nordic, who makes the vaccine, as well as individual member states.
Sewage surveillance
A team of researchers who used wastewater surveillance to track the incidence of COVID-19 is now turning their attention to monkeypox.
Surveillance and testing of sewage water has long held promise for the early detection of health threats but had limited applications before the COVID pandemic. In the US, such risk monitoring was largely confined to academic projects.
When COVID-19 emerged, a research group made up of scientists at Stanford University, the University of Michigan, and Emory University pioneered efforts to recalibrate surveillance techniques for detection of the virus, marking the first time that wastewater has been used to track a respiratory disease.
This research team, the Sewer Coronavirus Alert Network, is now expanding wastewater monitoring to detect monkeypox in the US.
Test kits
SaaS company WeTrade Group has struck a strategic partnership with Jiqing Biomedical Technology to produce monkeypox virus test kits and antigen tests.
Jiqing, a Chinese biotech focused on medical research and experimental development, created an antigen self-test kit for COVID-19 which was granted EU approval. With the emergence and spread of monkeypox, Jiqing developed a nucleic acid RT-LAMP test and a colloidal gold technique antigen test.
Working with Jiqing, WeTrade Group will leverage its digital tools to rapidly bring monkeypox virus test kits to market with the power of YCloud, a cloud intelligent system for microbusinesses, and its industry accumulation in computer technology and big data.
Therapeutics
SIGA Technologies confirmed this week that it will deliver $26 million worth of an intravenous formulation of smallpox drug TPOXX to the United States in 2023, after the US government elected to exercise certain procurement options.
Oral and intravenous formulations of TPOXX are approved by the US FDA for the treatment of smallpox, but not yet monkeypox. However, the US CDC provided guidance for its use under expanded access as an investigational drug.
The IV treatment will be a vital option for patients unable to swallow the oral pill as monkeypox symptoms include rashes and blisters in the mouth.
For more information on the global monkeypox response, read our recent feature: Vaccine industry must help fight monkeypox and secure supply chains
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Pharmapack 2024 - From the Floor
Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delive... -
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News CPHI Pharma Awards 2023 – API Development and Innovation Winners: Snapdragon Chemistry, a Cambrex Company
After another year of impressive nominations for the CPHI Pharma Awards our winners were announced at CPHI Barcelona in October. In this series of interviews, we speak to the teams behind the award-winning projects, concepts, and technologies. -
News PharmaKure gains authorisation for next stage testing on Alzheimer's treatment
Clinical stage pharmaceutical company PharmaKure gains permission from UK authorities to enter into further testing for PK051 for the treatment of patients with mild cognitive impairment associated with Alzheimer's disease. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News Navigating the Future: Challenges and Opportunities in Pharma Innovation and Investment – CPHI Barcelona 2023 Roundtable Report
In this comprehensive downloadable report, hear from a range of experts in finance and investment in the pharma industry on what investment trends will be shaping the future of the industry, in Catalonia, and the wider world. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance